Publications
NIBIOs employees contribute to several hundred scientific articles and research reports every year. You can browse or search in our collection which contains references and links to these publications as well as other research and dissemination activities. The collection is continously updated with new and historical material.
2023
Authors
Ana-Maria Madalina Pantazica Andre van Eerde Mihaela-Olivia Dobrica Iuliana Caras Irina Ionescu Adriana Costache Catalin Tucureanu Hege Særvold Steen Catalin Lazar Inger Heldal Sissel Haugslien Adrian Onu Crina Stavaru Norica Branza-Nichita Jihong Liu ClarkeAbstract
The recent SARS-CoV-2 pandemic has taught the world a costly lesson about the devastating consequences of viral disease outbreaks but also, the remarkable impact of vaccination in limiting life and economic losses. Vaccination against human Hepatitis B Virus (HBV), a major human pathogen affecting 290 million people worldwide, remains a key action towards viral hepatitis elimination by 2030. To meet this goal, the development of improved HBV antigens is critical to overcome non-responsiveness to standard vaccines based on the yeast-produced, small (S) envelope protein. We have recently shown that combining relevant immunogenic determinants of S and large (L) HBV proteins in chimeric antigens markedly enhances the anti-HBV immune response. However, the demand for cost-efficient, high-quality antigens remains challenging. This issue could be addressed by using plants as versatile and rapidly scalable protein production platforms. Moreover, the recent generation of plants lacking β-1,2-xylosyltransferase and α-1,3-fucosyltransferase activities (FX-KO), by CRISPR/Cas9 genome editing, enables production of proteins with “humanized” N-glycosylation. In this study, we investigated the impact of plant N-glycosylation on the immunogenic properties of a chimeric HBV S/L vaccine candidate produced in wild-type and FX-KO Nicotiana benthamiana. Prevention of β-1,2-xylose and α-1,3-fucose attachment to the HBV antigen significantly increased the immune response in mice, as compared with the wild-type plant-produced counterpart. Notably, the antibodies triggered by the FX-KO-made antigen neutralized more efficiently both wild-type HBV and a clinically relevant vaccine escape mutant. Our study validates in premiere the glyco-engineered Nicotiana benthamiana as a substantially improved host for plant production of glycoprotein vaccines.
Abstract
No abstract has been registered
Authors
Márk Rékási Péter Ragályi Déniel Benjámin Sándor Anita Szabó Pierre-Adrien Rivier Csilla Farkas Orsolya Szécsy Nikolett UzingerAbstract
No abstract has been registered
Abstract
No abstract has been registered
Authors
Joel Abbey Sherin Jose David Percival Laura Jaakola Samuel K. AsieduAbstract
No abstract has been registered
Authors
Darius KviklysAbstract
No abstract has been registered
Authors
Darius KviklysAbstract
No abstract has been registered
Authors
Ingrid Heyerdahl Juditte Juul Diab Ragnhild Nygaard Elisabeth Oterholt Peersen Wendy Fjellstad Sebastian EiterAbstract
No abstract has been registered
Authors
Fredrik Rustøen Klaus Høiland Einar Heegaard Lynne Boddy Alan C. Gange Håvard Kauserud Carrie Joy AndrewAbstract
No abstract has been registered
Abstract
No abstract has been registered